Therapy of Inflammatory Bowel Disease using New 5-ASA Compounds: An Introduction
Strong evidence has been accumulating that mesalazine (5- aminosalicylic acid, 5-ASA) represents the therapeutic moiety of the standard drug sulphasalazine. Since the active metabolite avoids the toxic potential of sulphapyridine, this perception has initiated new therapeutic approaches, for example...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1989-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/1989/434838 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548460317900800 |
|---|---|
| author | Ulrich Klotz |
| author_facet | Ulrich Klotz |
| author_sort | Ulrich Klotz |
| collection | DOAJ |
| description | Strong evidence has been accumulating that mesalazine (5-
aminosalicylic acid, 5-ASA) represents the therapeutic moiety of the standard
drug sulphasalazine. Since the active metabolite avoids the toxic potential of
sulphapyridine, this perception has initiated new therapeutic approaches, for
example, two 5-ASA molecules have been coupled to form another prodrug
(olsalazine) which again depends on a proper cleavage of the azobond by bacteria
in the colon A more direct way has been applied successfully by administering
5-ASA itself in special galenic formulation (suppositories, enemas, controlled release
preparations) to provide enough active material at the proposed sites of action in
the terminal ileum and/or colon. One major advantage of all 5-ASA compounds,
compared to sulphasalazine, is their 10-fold lower potential (incidence) for inducing
allergic reactions or causing intolerance. Aside from rare hypersensitivity reactions,
5-ASA can cause nausea. vomiting, headache and gastrointestinal disturbances
in 1 to 5% of patients. However, the new azocompound olsalazine induced
diarrhea or loose stool in at least 10 to 15% of the treated patients which might
limit its use in inflammatory bowel disease (IBD). In conclusion, the ‘old’ metabolite
5-ASA, in a ‘new’ design, offers an effective and very safe choice for the treatment of IBD. |
| format | Article |
| id | doaj-art-576a1ff4c9584396a5d93f3588b1a172 |
| institution | Kabale University |
| issn | 0835-7900 |
| language | English |
| publishDate | 1989-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology |
| spelling | doaj-art-576a1ff4c9584396a5d93f3588b1a1722025-02-03T06:13:57ZengWileyCanadian Journal of Gastroenterology0835-79001989-01-0132828410.1155/1989/434838Therapy of Inflammatory Bowel Disease using New 5-ASA Compounds: An IntroductionUlrich Klotz0Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, West Germany, GermanyStrong evidence has been accumulating that mesalazine (5- aminosalicylic acid, 5-ASA) represents the therapeutic moiety of the standard drug sulphasalazine. Since the active metabolite avoids the toxic potential of sulphapyridine, this perception has initiated new therapeutic approaches, for example, two 5-ASA molecules have been coupled to form another prodrug (olsalazine) which again depends on a proper cleavage of the azobond by bacteria in the colon A more direct way has been applied successfully by administering 5-ASA itself in special galenic formulation (suppositories, enemas, controlled release preparations) to provide enough active material at the proposed sites of action in the terminal ileum and/or colon. One major advantage of all 5-ASA compounds, compared to sulphasalazine, is their 10-fold lower potential (incidence) for inducing allergic reactions or causing intolerance. Aside from rare hypersensitivity reactions, 5-ASA can cause nausea. vomiting, headache and gastrointestinal disturbances in 1 to 5% of patients. However, the new azocompound olsalazine induced diarrhea or loose stool in at least 10 to 15% of the treated patients which might limit its use in inflammatory bowel disease (IBD). In conclusion, the ‘old’ metabolite 5-ASA, in a ‘new’ design, offers an effective and very safe choice for the treatment of IBD.http://dx.doi.org/10.1155/1989/434838 |
| spellingShingle | Ulrich Klotz Therapy of Inflammatory Bowel Disease using New 5-ASA Compounds: An Introduction Canadian Journal of Gastroenterology |
| title | Therapy of Inflammatory Bowel Disease using New 5-ASA Compounds: An Introduction |
| title_full | Therapy of Inflammatory Bowel Disease using New 5-ASA Compounds: An Introduction |
| title_fullStr | Therapy of Inflammatory Bowel Disease using New 5-ASA Compounds: An Introduction |
| title_full_unstemmed | Therapy of Inflammatory Bowel Disease using New 5-ASA Compounds: An Introduction |
| title_short | Therapy of Inflammatory Bowel Disease using New 5-ASA Compounds: An Introduction |
| title_sort | therapy of inflammatory bowel disease using new 5 asa compounds an introduction |
| url | http://dx.doi.org/10.1155/1989/434838 |
| work_keys_str_mv | AT ulrichklotz therapyofinflammatoryboweldiseaseusingnew5asacompoundsanintroduction |